NASDAQ
CURX
Last Price
US $0.21
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Curanex Pharmaceuticals Inc Common Stock cash flow to debt ratio of -3.02K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Curanex Pharmaceuticals Inc Common Stock's free cash flow has decreased 1.79K% from $-555.58K last year to $-10.48M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Curanex Pharmaceuticals Inc Common Stock's debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Curanex Pharmaceuticals Inc Common Stock has insufficient data to evaluate this check.
Financial stability - Net debt/EBITDA.
Curanex Pharmaceuticals Inc Common Stock has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Curanex Pharmaceuticals Inc Common Stock's interest coverage ratio of 736.38 indicates that earnings with good margin can cover interest payments on company debt
Financial risk - Profit margin growth.
Curanex Pharmaceuticals Inc Common Stock has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Curanex Pharmaceuticals Inc Common Stock's short-term assets of $11.23M exceed its short-term liabilities of $137.03K
Decreasing performance - ROA.
Curanex Pharmaceuticals Inc Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Curanex Pharmaceuticals Inc Common Stock's return on equity of -85.41%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Curanex Pharmaceuticals Inc Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Curanex Pharmaceuticals Inc Common Stock had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Curanex Pharmaceuticals Inc Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Curanex Pharmaceuticals Inc Common Stock has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Curanex Pharmaceuticals Inc Common Stock's yearly earnings has decreased 1.07K% since last year from $-361.51K to $-4.23M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Curanex Pharmaceuticals Inc Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Decreasing performance - ROIC.
ROIC -86.83% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Curanex Pharmaceuticals Inc Common Stock's 3-year revenue CAGR of -100.00% is negative, indicating declining revenue over the past 3 years
Decreasing performance - Revenue consistency.
Curanex Pharmaceuticals Inc Common Stock had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Curanex Pharmaceuticals Inc Common Stock had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Curanex Pharmaceuticals Inc Common Stock has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Curanex Pharmaceuticals Inc Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Curanex Pharmaceuticals Inc Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Curanex Pharmaceuticals Inc Common Stock has an EV/EBITDA ratio of 16.69x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Curanex Pharmaceuticals Inc Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Curanex Pharmaceuticals Inc Common Stock has a price-to-book ratio of 0.74x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Curanex Pharmaceuticals Inc Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-85.41%
Return on equity
ROIC: -86.83%
Valuation History
-0.82X
Price to Earnings
EV/EBITDA: -0.88X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $0.21
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.